Special report AI can study chemical molecules in ways scientists can't comprehend, automatically predicting complex protein structures and designing new drugs, despite having no real understanding of science. The power to design new drugs at scale is no longer limited to Big Pharma. Startups armed with the right algorithms, data, and compute can invent tens of thousands of molecules in just a few hours. New machine learning architectures, including transformers, are automating parts of the design process, helping scientists develop new drugs for difficult diseases like Alzheimer's, cancer, or rare genetic conditions. In 2017, researchers at Google came up with a method to build increasingly bigger and more powerful neural networks.
In 2021 the application of AI enabled advances in many areas of healthcare. We made significant progress in AI for drug discovery, medical imaging, diagnostics, pathology, and clinical trials. Important peer reviewed papers were published and dozens of partnerships were formed. Big Pharma companies and major tech companies became very active in the space. Record amounts of funding were raised, and a few companies even started human clinical trials. Microsoft and NVIDIA launched two of the world's most powerful supercomputers and Microsoft announced Azure OpenAI Service. In 2022 we expect these technologies to converge across the healthcare spectrum. This article summarizes milestones achieved in 2021. This is the first in a series of progress reports I'm writing on the sector that will be supplemented by industry performance data and metrics compiled in partnership with Alliance for Artificial Intelligence in Healthcare (AAIH) and other top tier resources.
The TriRhenaTech alliance presents the accepted papers of the 'Upper-Rhine Artificial Intelligence Symposium' held on October 27th 2021 in Kaiserslautern, Germany. Topics of the conference are applications of Artificial Intellgence in life sciences, intelligent systems, industry 4.0, mobility and others. The TriRhenaTech alliance is a network of universities in the Upper-Rhine Trinational Metropolitan Region comprising of the German universities of applied sciences in Furtwangen, Kaiserslautern, Karlsruhe, Offenburg and Trier, the Baden-Wuerttemberg Cooperative State University Loerrach, the French university network Alsace Tech (comprised of 14 'grandes \'ecoles' in the fields of engineering, architecture and management) and the University of Applied Sciences and Arts Northwestern Switzerland. The alliance's common goal is to reinforce the transfer of knowledge, research, and technology, as well as the cross-border mobility of students.
Objectives-Geriatric clinical care is a multidisciplinary assessment designed to evaluate older patients (age 65 years and above) functional ability, physical health, and cognitive wellbeing. The majority of these patients suffer from multiple chronic conditions and require special attention. Recently, hospitals utilize various artificial intelligence (AI) systems to improve care for elderly patients. The purpose of this systematic literature review is to understand the current use of AI systems, particularly machine learning (ML), in geriatric clinical care for chronic diseases. Materials and Methods-We restricted our search to eight databases, namely PubMed, WorldCat, MEDLINE, ProQuest, ScienceDirect, SpringerLink, Wiley, and ERIC, to analyze research articles published in English between January 2010 and June 2019. We focused on studies that used ML algorithms in the care of geriatrics patients with chronic conditions. Results-We identified 35 eligible studies and classified in three groups-psychological disorder (n=22), eye diseases (n=6), and others (n=7). This review identified the lack of standardized ML evaluation metrics and the need for data governance specific to health care applications. Conclusion- More studies and ML standardization tailored to health care applications are required to confirm whether ML could aid in improving geriatric clinical care.
Multimodal classification research has been gaining popularity in many domains that collect more data from multiple sources including satellite imagery, biometrics, and medicine. However, the lack of consistent terminology and architectural descriptions makes it difficult to compare different existing solutions. We address these challenges by proposing a new taxonomy for describing such systems based on trends found in recent publications on multimodal classification. Many of the most difficult aspects of unimodal classification have not yet been fully addressed for multimodal datasets including big data, class imbalance, and instance level difficulty. We also provide a discussion of these challenges and future directions.
Nowadays new technologies, and especially artificial intelligence, are more and more established in our society. Big data analysis and machine learning, two sub-fields of artificial intelligence, are at the core of many recent breakthroughs in many application fields (e.g., medicine, communication, finance, ...), including some that are strongly related to our day-to-day life (e.g., social networks, computers, smartphones, ...). In machine learning, significant improvements are usually achieved at the price of an increasing computational complexity and thanks to bigger datasets. Currently, cutting-edge models built by the most advanced machine learning algorithms typically became simultaneously very efficient and profitable but also extremely complex. Their complexity is to such an extent that these models are commonly seen as black-boxes providing a prediction or a decision which can not be interpreted or justified. Nevertheless, whether these models are used autonomously or as a simple decision-making support tool, they are already being used in machine learning applications where health and human life are at stake. Therefore, it appears to be an obvious necessity not to blindly believe everything coming out of those models without a detailed understanding of their predictions or decisions. Accordingly, this thesis aims at improving the interpretability of models built by a specific family of machine learning algorithms, the so-called tree-based methods. Several mechanisms have been proposed to interpret these models and we aim along this thesis to improve their understanding, study their properties, and define their limitations.
Hidden Markov models (HMMs) are commonly used for sequential data modeling when the true state of the system is not fully known. We formulate a special case of recurrent neural networks (RNNs), which we name hidden Markov recurrent neural networks (HMRNNs), and prove that each HMRNN has the same likelihood function as a corresponding discrete-observation HMM. We experimentally validate this theoretical result on synthetic datasets by showing that parameter estimates from HMRNNs are numerically close to those obtained from HMMs via the Baum-Welch algorithm. We demonstrate our method's utility in a case study on Alzheimer's disease progression, in which we augment HMRNNs with other predictive neural networks. The augmented HMRNN yields parameter estimates that offer a novel clinical interpretation and fit the patient data better than HMM parameter estimates from the Baum-Welch algorithm.
Over the past few years, we have seen fundamental breakthroughs in core problems in machine learning, largely driven by advances in deep neural networks. At the same time, the amount of data collected in a wide array of scientific domains is dramatically increasing in both size and complexity. Taken together, this suggests many exciting opportunities for deep learning applications in scientific settings. But a significant challenge to this is simply knowing where to start. The sheer breadth and diversity of different deep learning techniques makes it difficult to determine what scientific problems might be most amenable to these methods, or which specific combination of methods might offer the most promising first approach. In this survey, we focus on addressing this central issue, providing an overview of many widely used deep learning models, spanning visual, sequential and graph structured data, associated tasks and different training methods, along with techniques to use deep learning with less data and better interpret these complex models --- two central considerations for many scientific use cases. We also include overviews of the full design process, implementation tips, and links to a plethora of tutorials, research summaries and open-sourced deep learning pipelines and pretrained models, developed by the community. We hope that this survey will help accelerate the use of deep learning across different scientific domains.
Recent years have witnessed widespread adoption of machine learning (ML)/deep learning (DL) techniques due to their superior performance for a variety of healthcare applications ranging from the prediction of cardiac arrest from one-dimensional heart signals to computer-aided diagnosis (CADx) using multi-dimensional medical images. Notwithstanding the impressive performance of ML/DL, there are still lingering doubts regarding the robustness of ML/DL in healthcare settings (which is traditionally considered quite challenging due to the myriad security and privacy issues involved), especially in light of recent results that have shown that ML/DL are vulnerable to adversarial attacks. In this paper, we present an overview of various application areas in healthcare that leverage such techniques from security and privacy point of view and present associated challenges. In addition, we present potential methods to ensure secure and privacy-preserving ML for healthcare applications. Finally, we provide insight into the current research challenges and promising directions for future research.
Find here a listing of the latest industry news in genomics, genetics, precision medicine, and beyond. Updates are provided on a monthly basis. Sign-Up for our newsletter and never miss out on the latest news and updates. As 2019 came to an end, Veritas Genetics struggled to get funding due to concerns it had previously taken money from China. It was forced to cease US operations and is in talks with potential buyers. The GenomeAsia 100K Project announced its pilot phase with hopes to tackle the underrepresentation of non-Europeans in human genetic studies and enable genetic discoveries across Asia. Veritas Genetics, the start-up that can sequence a human genome for less than $600, ceases US operations and is in talks with potential buyers Veritas Genetics ceases US operations but will continue Veritas Europe and Latin America. It had trouble raising funding due to previous China investments and is looking to be acquired. Illumina loses DNA sequencing patents The European Patent ...